Erik Blackwood

Dr. Erik Blackwood


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
WSWinston Stauffer
Winston Stauffer
EBErik Blackwood
Erik Blackwood
KAKhalid Azizi
Khalid Azizi
RKRandal Kaufman
Randal Kaufman
CGChristopher Glembotski
Christopher Glembotski
Activating transcription factor-6 α (ATF6) is one of the three main sensors and effectors of the endoplasmic reticulum (ER) stress response and, as such, it is critical for protecting the heart and other tissues from a variety of environmental insults and disease states. In the heart, ATF6 has been shown to protect cardiac myocytes. However, its roles in other cell types in the heart are unknown. Here we show that ATF6 decreases the activation of cardiac fibroblasts in response to the cytokine, transforming growth factor β (TGFβ), which can induce fibroblast trans-differentiation into a myofibroblast phenotype through signaling via the TGFβ–Smad pathway. ATF6 activation suppressed fibroblast contraction and the induction of α smooth muscle actin (αSMA). Conversely, fibroblasts were hyperactivated when ATF6 was silenced or deleted. ATF6 thus represents a novel inhibitor of the TGFβ–Smad axis of cardiac fibroblast activation.

Verified
Journal Article
Open access
PDF file
WSWinston Stauffer
Winston Stauffer
AAAdrian Arrieta
Adrian Arrieta
EBErik Blackwood
Erik Blackwood
CGChristopher Glembotski
Christopher Glembotski
There are more than 2000 transcription factors in eukaryotes, many of which are subject to complex mechanisms fine-tuning their activity and their transcriptional programs to meet the vast array of conditions under which cells must adapt to thrive and survive. For example, conditions that impair protein folding in the endoplasmic reticulum (ER), sometimes called ER stress, elicit the relocation of the ER-transmembrane protein, activating transcription factor 6α (ATF6α), to the Golgi, where it is proteolytically cleaved. This generates a fragment of ATF6α that translocates to the nucleus, where it regulates numerous genes that restore ER protein-folding capacity but is degraded soon after. Thus, upon ER stress, ATF6α is converted from a stable, transmembrane protein, to a rapidly degraded, nuclear protein that is a potent transcription factor. This review focuses on the molecular mechanisms governing ATF6α location, activity, and stability, as well as the transcriptional programs ATF6α regulates, whether canonical genes that restore ER protein-folding or unexpected, non-canonical genes affecting cellular functions beyond the ER. Moreover, we will review fascinating roles for an ATF6α isoform, ATF6β, which has a similar mode of activation but, unlike ATF6α, is a long-lived, weak transcription factor that may moderate the genetic effects of ATF6α.

3 March 2020 in Cells
Verified
Journal Article
Open access
PDF file
EBErik Blackwood
Erik Blackwood
ABAlina S. Bilal
Alina S. Bilal
WSWinston Stauffer
Winston Stauffer
AAAdrian Arrieta
Adrian Arrieta
CGChristopher Glembotski
Christopher Glembotski
The heart exhibits incredible plasticity in response to both environmental and genetic alterations that affect workload. Over the course of development, or in response to physiological or pathological stimuli, the heart responds to fluctuations in workload by hypertrophic growth primarily by individual cardiac myocytes growing in size. Cardiac hypertrophy is associated with an increase in protein synthesis, which must coordinate with protein folding and degradation to allow for homeostatic growth without affecting the functional integrity of cardiac myocytes (i.e., proteostasis). This increase in the protein folding demand in the growing cardiac myocyte activates the transcription factor, ATF6 (activating transcription factor 6α, an inducer of genes that restore proteostasis. Previously, ATF6 has been shown to induce ER-targeted proteins functioning primarily to enhance ER protein folding and degradation. More recent studies, however, have illuminated adaptive roles for ATF6 functioning outside of the ER by inducing non-canonical targets in a stimulus-specific manner. This unique ability of ATF6 to act as an initial adaptive responder has bolstered an enthusiasm for identifying small molecule activators of ATF6 and similar proteostasis-based therapeutics.

18 March 2026 in Journal of Molecular and Cellular Cardiology
Verified
Journal Article
Open access
PRPukjera J. Rungreang
Pukjera J. Rungreang
SNSean Noudali
Sean Noudali
EBErik Blackwood
Erik Blackwood
YTYow Keat Tham
Yow Keat Tham
The human heart has often been described as the "metronome of life" beating continuously over 2.5 billion times across the average lifespan and consuming more than 6 kg of ATP daily. And, during both a healthy and diseased state, the heart predominately relies on the oxidation of fatty acids to fuel its contractile burden of supporting all other organ systems. While metabolic alterations and substrate utilization inflexibility have been well studied and are considered hallmarks of heart failure pathogenesis, the overwhelming majority of these investigations have focused on the health and function of the mitochondria in cardiac myocytes; for good reason given the mitochondria is the location of oxidative phosphorylation complexes that, although debated, can form respiratory super complexes to generate ATP in conjunction with the electron transport chain and TCA cycle. However, there exists a potentially overlooked supporting organelle crucial for fatty acid oxidation - the peroxisome. In addition to serving as the site of long chain fatty acid breakdown into acyl-CoA for transport into the mitochondria, the peroxisome supports cellular viability and function via several critical mechanisms (e.g. plasmalogen synthesis and reactive oxygen species quenching). Despite this, only recently have published reports started to appreciate the potential significance of peroxisomes in cardiovascular physiology. In this review, we aim to provide a global perspective on peroxisomes to include their lifecycle and function gathered mostly from seminal studies in extracardiac tissues and highlight functional roles for peroxisomes directly in the context of cardiac physiology and pathology from more recent literature.

14 April 2026 in Journal of Molecular and Cellular Cardiology Plus
Verified
Journal Article
Open access
SBSukriti Bagchi
Sukriti Bagchi
ACAmy Cai
Amy Cai
ABAlina S. Bilal
Alina S. Bilal
JGJavier Gamez-Luque
Javier Gamez-Luque
MRManuel Rosa-Garrido
Manuel Rosa-Garrido
EBErik Blackwood
Erik Blackwood
Advances in cancer treatments have enabled long-term patient survival at increasing rates, however these therapies often have chronic adverse side effects of which cardiovascular disease is a major cause for concern. Specifically, patients treated with the anthracycline, doxorubicin (DOX), face significantly higher rates of delayed-onset heart failure (HF), clinically referred to as chronic DOX-induced cardiotoxicity (DIC), typically years or even decades following treatment despite showing no observable signs of acute cardiotoxicity. In patients, even low-dose DOX is known to induce cardiac fibrosis which increases the risk for HF, thus, implicating the cardiac fibroblast (CFB) as having a prominent role in chronic DIC. To determine possible roles for CFB in DIC we developed in vitro and in vivo models that tested the immediate and delayed effects of DOX administered at concentrations that mimic those used clinically. While, at these levels, DOX had very little effect on CFB viability in vitro, it did increase markers of CFB activation and dramatically altered the CFB transcriptome. These effects persisted even when CFB were subsequently treated with the canonical differentiation stimulus, transforming growth factor-β (TGFβ), consistent with a cellular memory of prior DOX exposure. In our in vivo model in mice, clinically relevant doses of DOX had essentially no effect on cardiac structure and function, however, prior exposure to DOX exacerbated cardiac dysfunction and structural remodeling in response to a subsequent stressor in the form of chronic angiotensin II/phenylephrine (ANGII/PE) infusion mimicking the effects of a common ailment (i.e. hypertension) DIC patients often face later in life. At the molecular level, DOX increased markers of CFB activation and cardiac fibrosis in mouse hearts in response to ANGII/PE that was coordinate with the severity of cardiac dysfunction. In summary, our mouse model mimicked the delayed deleterious effects of DOX on cardiac structure and function, suggesting that despite exhibiting no effect on CFB viability, DOX promotes maladaptive cardiac remodeling through an exaggerated response to a delayed stimulus that ultimately results in an exacerbated progression into HF.